Last Updated : November 14, 2023
Details
Generic Name:
nirmatrelvir/ritonavir
Project Status:
Active
Therapeutic Area:
Mild-to-moderate COVID-19, treatment
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Paxlovid
Project Line:
Reimbursement Review
Project Number:
SR0808-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 03-Aug-23 |
|---|---|
| Call for patient/clinician input closed | 25-Sep-23 |
| Clarification: - Patient input submission received from the Gastrointestinal Society, Lung Health Foundation, Save Your Skin Foundation and Sickle Cell Awareness Group of Ontario | |
| Submission received | 15-Sep-23 |
| Submission accepted | 29-Sep-23 |
| Review initiated | 03-Oct-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 07-Nov-23 |
| Deadline for sponsors comments | 14-Nov-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 08-Dec-23 |
| Expert committee meeting (initial) | 20-Dec-23 |
| Draft recommendation issued to sponsor | January 09, 2024 To January 11, 2024 |
| Draft recommendation posted for stakeholder feedback | 18-Jan-24 |
| End of feedback period | 02-Feb-24 |
Last Updated : November 14, 2023